Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).
2026年6月16日 更新者:Oystershell NV
In Vivo Testing : A Two-Arm, Randomized, Controlled, Investigator/Assessor-Blinded, Comparative Study to Evaluate the Safety, Efficacy, and Preventative Effect of a Head Lice Physically Acting Product: 2 in 1 SHAMPOO EU VERSION (X92001483) vs NIX CREME RINSE (1% Permethrin) in Subjects With Head Lice.
To compare the safety, effectiveness, and preventive benefits of a medical device (X92001483) against Nix Cream Rinse (1% Permethrin) in people with head lice
調査の概要
詳細な説明
Compare Safety, Efficacy and preventative effect of a medical device with a physical mode of action against Nix Cream Rinse (1% Permethrin) in Subjects with Head Lice in a two-arm, randomized, controlled, Investigator/Assessor-blinded comparative study.
研究の種類
介入
入学 (推定)
98
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Katie Shepherd
- 電話番号:561-635-2884
- メール:katie@licesolutions.org
研究場所
-
-
Florida
-
Maitland、Florida、アメリカ、32751
- 募集
- LSRN
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Gender: male / female.
- The subject or his/her parent/legal guardian (from age 12-17) must give written informed consent (after having been informed orally and by written text about the benefits and potential risks of the trial, as well as information regarding the insurance, taken out to cover the subjects participating in the study). A caregiver must sign an informed consent agreement for children not old enough to do so. Children aged 6-11 years of age will be administered a child's assent form. The subject or his/her parent/legal guardian must be capable of understanding and providing written informed consent.
- Age ≥ 1 year of age at the time of enrollment.
- Subject agree to not use any other anti-lice or preventative treatment or medicated hair grooming products for the duration of the study (through last visit day- Day 14).
- Subject must have an active head lice infestation defined as at least 5 live lice (adults and/or nymphs) and 5 live nits based on magnified observations, present on the scalp and/or hair, as determined by a trained evaluator.
- The subject is in good general health based on medical history.
- Female subjects of childbearing potential must have a negative pregnancy test at screening and agree to use a reliable method of birth control (as described in section 7.8) during duration of the study.
- The parent or legal guardian of a child subject must consent to the screening of other household members for head lice. If additional household members are found to have head lice and meet eligibility criteria, they must be enrolled in the study for all household members to qualify for participation.
- Have a single place of residence or agree to remain at the current residence for the duration of the study.
- Subject agrees not to additionally shampoo, wash, or rinse their hair or scalp for 24-hours post treatment.
- The subject agrees not to cut or chemically treat their hair while participating in the study.
- Subject agrees to follow all study instructions, including attending all follow-up appointments.
Exclusion Criteria:
- Application of any form of head lice treatment, whether prescription or over-the counter (OTC), or home remedy for 14 days prior to their screening visit (Visit 1).
- Application of any topical medication of any kind on the hair or scalp for a period of 48 hours prior to the screening visit.
- Use of systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results.
- Known skin allergies, multiple drug allergies or multiple allergies to cosmetic products.
- History of allergy or hypersensitivity to active ingredients, or constituents of the investigational or comparator products.
- Subject with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel, will interfere with the evaluation of the investigational product.
- Subjects with chronic scalp disorder.
- Subject or his/her legal guardian who, in the opinion of the investigative personnel, do not understand the subject requirements for study participations and/or may be likely to exhibit poor compliance with the required visits.
- Females who are pregnant or nursing.
- Hair longer than waist length.
- Subject suspected or known not to follow instructions
- Previous participation in this study or participation in any other investigational trial within the preceding 14 days.
- The subject is directly affiliated to the investigator site personnel and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- The subject is an Oystershell employee or is an employee of a third-party organization involved in the study.
- People with dreadlocks or clips in hair that cannot be removed or a person who does not want to remove these.
- Hair that is too difficult to work with as assessed by the study staff.
- Families excluded where lice exist however a family member decline enrollment in the study.
- Subjects who are receiving, or are expected to receive, any antibiotic therapy during the study period will be excluded.
- No more than one working male subject per household may be excluded from evaluation if determined to be lice free by self-report or caregiver observation.
- All household members of the subject, other than excluded male adult, must be screened for head lice by a certified head lice professional. If additional household members are found to have head lice and meet the study criteria, they will be referred to LSRN Research and enrolled in study. If a household member declines enrollment, all family members will be excluded from the study.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Medical Device X92001483
Treatment of subjects with head Lice with the standard of care product Nix Creme Rinse on day 0 and day 7, followed by intermediate application of the medical device (X92001483) with a physical mode of action applied every 3 days.
|
Treatment of subjects with Head Lice with a medical device (X92001483) with a physical mode of action on day 0, day 7, day 10, day 13 and day 14.
|
|
介入なし:Nix Cream Rinse (1% Permethrin)
Treatment of subjects with Head Lice with Nix Cream Rinse (1% Permethrin) with a physical mode of action on day 0 and day 7.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Preventative Effect
時間枠:14 days
|
Determin whether subjects treated with the medical device X92001943 after treatment with Nix Creme Rinse maintain a higher cure rate at the end of the study compared with subjects treated only with Nix Creme Rinse.
|
14 days
|
|
Maintenance of cure rate over time
時間枠:day 3, day 7, day 10, day 13 and day 14
|
To assess the maintenance of cure over time: To compare cure rates between subjects treated with Nix Creme Rinse and the medical device X92001483 at interim visits in order to evaluate the presence and persistence of the preventive effect of the investigational product relative to standard of care product (Nix creme rinse) alone.
|
day 3, day 7, day 10, day 13 and day 14
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to re-infestation
時間枠:14 days
|
Characterize the time to re-infestation in each treatment group
|
14 days
|
|
Number of live lice
時間枠:Day 0, day 3, day 7, day 10, days 13, day 14
|
To compare the number of live lice detected at each assessment across treatment groups.
|
Day 0, day 3, day 7, day 10, days 13, day 14
|
|
Local tolerability
時間枠:day 0, day 3, day 7, day 10, day 13 and day 14
|
To evaluate the local tolerability of the standard of care product and investigational product, as measured by subject reported symptoms (eg: burning, paraesthesia, pruritus) following application.
|
day 0, day 3, day 7, day 10, day 13 and day 14
|
|
Scalp and skin irritation
時間枠:day 0, day 3, day 4, day 7, day 10, day 13 and day 14
|
To evaluate scalp and skin irritation by study staff (secondary infection, erythema, excoriation) following product application.
|
day 0, day 3, day 4, day 7, day 10, day 13 and day 14
|
|
Adverse advents
時間枠:Day 0, day 3, day 7, day 10, day 13 and day 14
|
To record and characterize all treatment-emergent adverse events occurring during the study.
|
Day 0, day 3, day 7, day 10, day 13 and day 14
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
協力者
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2026年5月1日
一次修了 (推定)
2026年9月1日
研究の完了 (推定)
2026年12月1日
試験登録日
最初に提出
2026年6月16日
QC基準を満たした最初の提出物
2026年6月16日
最初の投稿 (実際)
2026年6月22日
学習記録の更新
投稿された最後の更新 (実際)
2026年6月22日
QC基準を満たした最後の更新が送信されました
2026年6月16日
最終確認日
2026年6月1日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- OYS012-0025
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。